Neuropeptide Y (NPY), whose role in appetite regulation is well known, is also expressed in pancreatic islets. Although previous studies indicated that application of NPY to pancreatic islets inhibits insulin secretion, its physiological role in the regulation of insulin secretion is not fully understood. We hypothesized that NPY in islets tonically suppresses insulin secretion and the reduction of islet NPY increases insulin secretion. To address the hypothesis, islet function of NPYdeficient mice was analyzed. Although there was little change in glucose homeostasis in vivo, pancreatic islets from NPYdeficient mice had higher basal insulin secretion (1.5 times), glucose-stimulated insulin secretion (1.5 times), and islet mass (1.7 times), compared with wild-type mouse. Next we sought to determine whether the expression of NPY and Y 1 receptor in islets was altered in hyperinsulinemia associated with obesity. Islets from C57BL/6J mice on a high-fat diet had 1.9 times higher basal insulin secretion and 2.4 times higher glucosestimulated insulin secretion than control mice, indicating islet adaptation to obesity. Expression of NPY and Y 1 receptor mRNA levels was decreased by 70 and 64%, respectively, in high-fat diet islets, compared with controls. NPY and Y 1 receptor in islets were also reduced by 91 and 80%, respectively, in leptin-deficient ob/ob mice that showed marked hyperinsulinemia. Together these results suggest that endogenous NPY tonically inhibits insulin secretion from islets and a reduction of islet NPY may serve as one of the mechanisms to increase insulin secretion when islets compensate for insulin resistance associated with obesity. (Endocrinology 148:  5716 -5723, 2007) 
T HE INCIDENCE OF type 2 diabetes is increasing as a
consequence of the obesity epidemic (1, 2) . Normally insulin resistance associated with obesity is compensated by increasing pancreatic islet mass and insulin secretion (3) (4) (5) . However, in some patients ␤-cell adaptation is attenuated, leading to the onset of diabetes and related complications (4) . Currently the underlying mechanism responsible for islet adaptation in obesity is not fully understood. Interestingly, some of neuropeptides implicated in the regulation of energy homeostasis in the brain are also expressed in pancreatic islets and may serve as a link between energy and glucose homeostasis (6, 7) .
Neuropeptide Y (NPY) belongs to the pancreatic polypeptide family, which includes peptide YY and pancreatic polypeptide (8) . NPY is one of the best-characterized orexigenic peptides and is well known to stimulate feeding, decrease energy expenditure, and increase body weight through its action on G protein-coupled receptors (Y 1 and Y 5 ) in the hypothalamus and other regions of the brain (9) . NPY is also expressed in pancreatic islets and is implicated in the regulation of islet function (10 -14) . In islets, NPY is colocalized in glucagon, somatostatin, and insulin-producing cells (10 -14) . NPY decreases glucose-stimulated insulin secretion from the rat pancreas and islets (14, 15) , rat insulinoma cells (16) , mouse pancreas and islets (17, 18) , and human islets (19) . Conversely, immunoneutralization of NPY acutely increases insulin secretion from rat islets (20) . Thus, NPY may act through a paracrine or autocrine mechanism to tonically inhibit insulin secretion. However, little is known whether islet NPY has any physiological role in the regulation of glucose homeostasis.
In this study we addressed the functional role of islet NPY in knockout mice. We found that NPY deficiency increased basal and glucose-stimulated insulin secretion and islet mass. Furthermore, the expression of NPY and its receptors was decreased in obese rodents characterized with hyperinsulinemia. Together these results indicate that the reduction of NPY in pancreatic islets may remove suppression on insulin secretion and may play a role in the regulation of islet function in obesity.
Biochemical analyses
Blood glucose measurements were obtained from tail vein bleeding using OneTouch Ultra glucometer (Lifescan; Johnson & Johnson, Milpitas, CA). Serum harvested from cardiac puncture was centrifuged at 500 ϫ g at 4 C for 20 min and stored at Ϫ20 C for assays. Serum insulin levels were measured with rat insulin ELISA kit using mouse insulin standards from Crystal Chem Inc. (Chicago, IL).
Glucose tolerance test and insulin tolerance test
For the oral glucose tolerance test, mice were fasted overnight and were given 3 g/kg body weight (BW) glucose by gavage and blood glucose (0, 30, 60, 120, 180, and 240 min), and insulin measurements (0 and 15 min) were obtained from tail vein bleeding. For the insulin tolerance test, mice were fasted for 4 h and were given 0.75 U/kg BW human regular insulin ip, and blood glucose measurements were obtained from tail vein bleeding.
Islet isolation, ex vivo perifusion assay, and batch assay
Mice were anesthetized with sodium pentobarbital (50 mg/kg BW, ip), and pancreatic islets were isolated using collagenase digestion followed by Ficoll density gradient centrifugation as was described before (23, 24) . For the perifusion assay, around 100 freshly isolated islets were loaded to a perifusion apparatus and perifused for 35 min with the Krebs buffer (pH 7.4) containing 2.2 mm Ca 2ϩ , 0.25% BSA, and 10 mm HEPES under 5% CO 2 atmosphere at 37 C in the absence of glucose followed by the Krebs buffer with increasing concentration of glucose ramp from 0 to 30 mm at 0.8 mmol/min. At the end of each experiment, islets were tested for the maximum insulin secretion by adding 30 mm KCl in the perifusate (25, 26) . Samples were collected at 1 ml/min for insulin measurement by RIA (Linco research, Inc., St. Charles, MO). At the end of experiments, islets in a perifusion apparatus were recovered on the filter and stored at Ϫ80 C for DNA and insulin measurement. For the batch assay, isolated islets were cultured 1 d in RPMI 1640 supplemented with 10% fetal bovine serum, 10 mm glucose, penicillin, and streptomycin at 37 C in a 5% CO 2 incubator. Five islets were transferred into 200 l of the Krebs buffer without glucose and preincubated for 1 h at 37 C in a 5% CO 2 incubator. Then buffer was changed to 200 l of the Krebs buffer with the indicated concentration of glucose in the presence or absence of 500 nm NPY, and incubation was carried out 1 h at 37 C in a 5% CO 2 incubator.
Islet DNA and insulin contents
After perifusion assay, the islets were suspended in 500 l of 10 mm Tris HCl, 1 mm EDTA, and 0.2 m NaCl (pH 7.4) and sonicated to obtain islet homogenate. DNA content in islet homogenate was measured using bisBENZIMIDE (Sigma, St. Louis, MO) according to the manufacturer's instructions (27) . Insulin was extracted by adding 10 times the volume of 75% EtOH containing 0.18 n HCl to islet homogenate and incubating at 4 C overnight. Insulin measurement was performed by RIA.
Histology
The pancreas was removed from diet-induced obesity (DIO), ob/ob, and NPY-deficient mice, and control mice were weighed, fixed in 10% buffered formalin overnight, and embedded in paraffin. Pancreatic sections were deparaffinized, boiled 6 min in 10 mm citric acid (pH 6.0) for antigen retrieval and incubated sequentially with avidin, biotin, and protein blocking agent (Immunotech, Cedex, France) to block nonspecific binding sites. Slides were serially incubated with 1:400 guinea pig antiinsulin antibody (Dako Diagnostics, Cambridgeshire, UK) at 4 C over night, 1:400 biotinylated anti-guinea pig antibody (Vector Laboratories, Burlingame, CA) at 37 C for 1 h and avidin/biotin complex (ABC; Vectastain Elite ABC kit; Vector Laboratories) at 37 C for 1 h. Color development was performed with diaminobenzidine (Vector Laboratories) according to the manufacturer's protocol. Alternatively, insulin was visualized by 1:800 Cy2-conjugated donkey anti-guinea pig antibody (Jackson ImmunoResearch, West Grove, PA). Image of a pancreatic section with the maximum footprint from each mouse was captured by a color video camera attached to a light microscope (Nikon, Tokyo, Japan). Pancreas area and ␤-cell area were measured using IP lab (Scanalytics, Fairfax, VA). Islet area (percent) was calculated as ␤-cell area/ pancreas area.
RNA extraction and genes expression analyses
Islet RNA was extracted from isolated islet using RNeasy kit (QIA-GEN, Valencia, CA), and cDNA was generated by SuperScript Choice System for cDNA synthesis (Invitrogen, Carlsbad, CA) using 500 ng of islet RNA as a template. The expression of genes was analyzed by ABI Prism 7900HT sequence detection system (Applied Biosystems, Foster City, CA) with commercial primers for the system. The results were expressed using 36B4 gene expression as an internal standard.
Statistics
The data are presented as mean Ϯ sem. Differences between two groups were assessed with unpaired Student's t test. Multiple parameters were analyzed by ANOVA test. P Ͻ 0.05 was considered significant.
Results

NPY deficiency increases insulin secretion
We used NPY null mice to investigate the functional role of NPY in glucose homeostasis. As we have previously reported (22) , ablation of the Npy gene did not affect body weight or glucose levels when the mice were fed a regular chow diet (Fig. 1, A and B) . Although fasting insulin levels were not different between NPY-deficient mice and control mice, serum insulin levels were 2.0-fold higher in NPY-deficient mice fed ad libitum (Fig. 1C) . There was not significant difference in blood glucose or insulin levels on oral glucose challenge between NPY-deficient mice and control mice (Fig.  1, D and E) . Insulin tolerance test demonstrated that blood glucose levels were lower in NPY-deficient mice that could be either due to higher insulin sensitivity or decreased counterregulatory response, compared with control mice (Fig. 1F , two-way ANOVA, P Ͻ 0.05). Thus, mice deficient of NPY in whole body had only subtle change in glucose homeostasis, compared with wild-type mice as reported before (28) . However NPY-deficient mice demonstrated elevated serum insulin levels while being insulin tolerant. This, together with the previous demonstration of suppressive effect of exogenous NPY on insulin secretion, prompted us to further evaluate the function of islets isolated from NPY-deficient mice using ex vivo perifusion assay (14 -20) . NPY-deficient islets had higher basal insulin secretion, glucose-stimulated insulin secretion, and area under the curve (AUC) insulin than wild-type mice (Fig. 2, A and B ; two-way ANOVA, P Ͻ 0.05).
As reported before (14 -20) , exogenous NPY significantly decreased glucose-stimulated insulin secretion from NPYdeficient islets (Fig. 2C) . To address whether the higher insulin secretion in NPY-deficient islet was due to increased islet cell number, we compared the DNA and insulin contents of isolated islets with wild-type islets. DNA contents of islets were similar between NPY null and wild-type mice (13.6 Ϯ 3.1 ng/islet in wild type vs. 13.6 Ϯ 2.5 ng/islet in NPY null). Insulin contents normalized to DNA tended to be higher in NPY null mice ( Fig. 2C ; P ϭ 0.05). Morphometric analysis of the pancreas revealed greater islet area in NPY null mouse than wild type ( Fig. 2D , P Ͻ 0.05). Real-time PCR did not show significant difference in mRNA expression of Y 1 receptor, peptide YY, pancreatic polypeptide, glucagon, and somatostatin between NPY-deficient islets and control (data not shown). The expression of Y 5 receptor was not detectable in NPY-deficient islets or control.
Obesity increases insulin secretion and islet mass and reduces islet NPY and Y 1 receptor
After 12 wk on a high-fat diet, body weight was 132% higher in DIO mice (Fig. 3A) . This was accompanied by increases in glucose (1.2-fold) and insulin (2.7-fold) levels in DIO mice, compared with mice on regular chow diet (Fig. 3,  B and C) . In the perifusion assay, basal insulin secretion was 1.9-fold higher in islets from DIO than regular chow-fed mice (Fig. 3D , two-way ANOVA, P Ͻ 0.05). Moreover, the AUC of glucose-stimulated insulin secretion was 2.4-fold higher in DIO than regular chow-fed mice (P Ͻ 0.05). To address whether the higher insulin secretion in DIO was due to increased islet cell number, the DNA and insulin contents of isolated islets were compared with controls. The DNA contents of DIO islets were 114% of control (6.9 Ϯ 0.6 ng/islet in control vs. 7.8 Ϯ 0.5 ng/islet in DIO) and did not attain statistical significant difference (P ϭ 0.36). On the other hand, insulin contents adjusted for DNA increased 3.3-fold in DIO islets (P Ͻ 0.05). Morphometric analysis of pancreatic sections revealed an increase in islet area in DIO (Fig. 3E, 3 .2-fold, P Ͻ 0.01). Thus, both insulin secretion and islet mass were increased in obese DIO mice, indicating islet adaptation to insulin resistance.
We further examined the relationship among obesity, glucose homeostasis, and islet compensation in ob/ob mice. In agreement with previous reports (29, 30) , ob/ob mice were mor- bidly obese, hyperinsulinemic, and hyperglycemic (Fig. 4 , A-C). Perifusion of islets revealed a higher glucose stimulated insulin secretion in ob/ob, compared with wild-type mice (Fig.  4D , two-way ANOVA, P Ͻ 0.05). In contrast to DIO islets, basal insulin secretion was not elevated in ob/ob islets (Fig. 4D ). Islets were markedly enlarged in ob/ob mice, compared with wildtype mice, as reported before (31) (Fig. 4E) . Because NPY deficiency increased insulin secretion and islet mass in NPY null mice, we addressed whether NPY contributes to islet adaptation in obesity by analyzing the expression of NPY Y 1 and Y 5 receptors using real-time PCR. In DIO islets, insulin mRNA levels were 1.5-fold higher than controls, although statistically not significant (P ϭ 0.23). NPY and Y 1 receptor mRNA levels were reduced by 70 and 64%, respectively, in DIO (Fig. 5, A 
Discussion
In the present study, NPY null mice had higher serum insulin levels in fed status while being insulin intolerant, and insulin secretion was elevated in NPY-deficient islets ex vivo. The previous studies showed that addition of NPY to pancreatic islets suppresses glucose stimulated insulin secretion via activation of Y 1 receptor (14 -20) . In addition neutralization of NPY in isolated islets acutely increases insulin secretion (20) . Taken together, it appears that NPY in islets normally exerts a tonic inhibition on insulin secretion, and the reduction of NPY in islets augments insulin secretion. Interestingly, NPY and Y 1 receptor were both decreased in islets of DIO and ob/ob mice, which is associated with elevated circulating insulin levels, higher glucose-stimulated insulin secretion from isolated islets, and increased islet area. Therefore, the reduction of NPY and Y 1 receptor levels in DIO and ob/ob islets may promote islet adaptation to the increasing demand for insulin in obesity.
Several neuropeptides that are known to play important roles in energy homeostasis are also expressed in pancreatic islets (6) . Leptin, melanin-concentrating hormone, ghrelin, galanin, orexins A and B, and TRH are all found in pancreatic islets and reported to affect islet function and/or growth locally (6, (32) (33) (34) (35) (36) (37) . TRH-deficient mice develop glucose intolerance due to decreased insulin secretion (32). Pissios et al. (37) reported that melanin-concentrating hormone in pancreatic islets increases islet size and insulin secretion. Our study presents additional support that neuropeptides in islets are important regulators of islet function. Admittedly the change in glucose homeostasis in whole-body NPY-deficient mice on regular rodent chow was very subtle, and elevated serum insulin levels at fed status could be multifactorial. Ultimately it requires the studies of islet-specific overexpression/down-regulation of NPY to clarify the contribution of pancreatic NPY to glucose homeostasis in vivo. It has been proposed that the communication between the brain and pancreatic islets is important in integration of islet function with energy homeostasis (7) . Innervation to pancreatic islets is a potential link that coordinates insulin secretion with energy status (38) . In addition, the neuropeptides that are found in both the brain and pancreatic islets may act together to increase insulin secretion during the higher metabolic demands of obesity. However, the present study did not provide the evidence of concordance between the brain NPY and pancreatic NPY at the level of mRNA expressions. In DIO and ob/ob mice, leptin resistance and deficiency contribute to up-regulation of hypothalamic NPY (39, 40) . In contrast, we found that NPY and its receptors are reduced in pancreatic islets of these mice. Nevertheless, we cannot exclude the possibility that central NPY as well as pancreatic NPY contributes to islet adaptation in obesity. Up-regulation of central NPY has been shown to increase insulin secretion through parasympathetic stimulation, which is opposite of its paracrine action in pancreatic islets (6, 41) . Therefore, future study should address whether the central activation of NPY works along with the reduction of islet NPY to increase insulin secretion in insulin resistance status.
The mechanisms responsible for suppression of NPY and Y 1 receptor in obese rodent islets in our study await further study. Glucocorticoids have been demonstrated to induce NPY expression in the brain and may partly mediate the rise in hypothalamic NPY levels in ob/ob mice (42) . Dexamethasone was also shown to increase NPY expression in pancreatic islets (12, 13, 20) . However, this effect is opposite to the reduction of islet NPY levels in ob/ob and DIO islets in the current study. Both increase and reduction of NPY expression on glucose stimulation were reported in islets and insulinoma cell lines (20, 43, 44) . In rat insulinoma cells, prolactin and deprivation of glucose increased NPY expression in part through the activation of AMP-activated protein kinase (44) . It is possible that alterations in glucose, lipids, cytokines, and various metabolites associated with obesity contribute to the reduction in NPY and Y 1 receptor in islets and ultimately trigger changes in islet mass and function.
Recently Freeman et al. (45) reported that C57BL/6J mice harbor the genetic defect in nicotinamide nucleotide transhydrogenase that impairs glucose stimulated insulin secretion. Interestingly our study and others show that C57BL/6J mice are capable of enhancing insulin secretion and islet size in response to insulin resistance. The significance of adaptive hyperinsulinemia in the maintenance of glucose levels was previously reported in DIO and ob/ob mice in C57BL/6J (28, 46) . Currently the mechanisms responsible for islet adaptation to insulin resistance are not fully understood (5) . There are substantial evidences that growth factors and metabolites including insulin/IGF-I signaling and glucose play critical roles in increasing islet mass and insulin secretion under insulin resistance (47) (48) (49) . The present study implies that the suppression of NPY and Y 1 receptor may also increase insulin secretion and islet size in obesity.
We found that islet mass was increased in Npy null mice. In contrast, exogenous NPY increased ␤-cell replication in cultured islet (50) . The discrepancy between in vivo and in vitro studies is not clear at this point. Because there was little change in DNA contents per islet in our study, hypertrophy rather than hyperplasia may play a dominant role in increasing islet mass in NPY-deficient mice. Further studies are needed to evaluate how NPY affects ␤-cell proliferation and death and islet secretory function during the evolution of DIO and genetic obesity. Moreover, it would be interesting to determine how NPY action in the islet is related to its overall action on energy homeostasis. In summary, we have determined that insulin secretion and islet size are increased in NPY-deficient islets. The expression of NPY and Y 1 receptor was suppressed in islets of obese mice that showed expansion of pancreatic islets, increased insulin secretion, and high levels of insulin in the circulation. Therefore, the suppression of NPY and Y 1 receptor may play a functional role in increasing islet mass and insulin secretion in obesity. Potentially, NPY or signaling pathways mediated by the NPY and Y 1 receptor may be targeted for the prevention and treatment of ␤-cell dysfunction in obesity.
